Gary Lyons has been a member of the board of directors of Travere Therapeutics, Inc. since 2014 and assumed the role of chairman in May of 2016. Previously, Mr. Lyons was the founding president and chief executive officer of Neurocrine Biosciences from 1993 to 2008 and remains as a member of the board of directors. Prior to his work at Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including vice president of business development and vice president of sales. Mr. Lyons currently serves as chairman of the board of directors for Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. He also serves as a director for Vical Incorporated, a biotechnology company focused on the prevention and treatment of serious or life-threatening diseases. Mr. Lyons was previously a director of PDL BioPharma, Inc., NeurogesX, Inc., and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an MBA from Northwestern University’s J.L. Kellogg Graduate School of Management.